Zila Nutraceuticals, Inc. Attributes New Research, Form Differentiation, and Marketing Support to Sales Growth
PRESCOTT, Ariz. (April 26, 2005) – Zila Nutraceuticals, Inc., maker of Ester-C®, announces growing retail sales for Ester-E, its unique, patented form of vitamin E. The magnitude of this growth is realized when compared with the downward trend of the vitamin E category, and the recent negative press on vitamin E.
According to A.C. Nielsen (via SPINS), the vitamin E category continues to be down more than 40 percent versus last year on a dollar basis since the November 10 Johns Hopkins study was publicized. In the past 12-week period ending March 19, 2005, the category was reported down -42 percent in Food, Drug, and Mass Merchandisers. However, for the same period, Ester-E sales continue to increase, up +35 percent on a dollar basis versus the previous 12-week period ending December 25, 2004*.
“In a category that has been reeling due to negative press, there is one form of vitamin E that is shining – Ester-E,” said Ken Vargha, director of marketing for Zila Nutraceuticals. “We believe that Ester-E is succeeding because it is a unique form of the vitamin, and we’re investing millions of dollars to help educate consumers about the difference.”
The difference of Ester-E from other forms of vitamin E, as evidenced by previously published in vitro and animal studies, continues with the most recent animal study. In this study, conducted by Monash University in Australia, the LDL cholesterol (the “bad” cholesterol) in mice supplemented with Ester-E was reduced by up to 40 percent. Triglycerides were significantly reduced in the same population, while the population supplemented with regular vitamin E (d-alpha-tocopheryl acetate) showed no effect in this study. When coupled with previous positive in vitro studies, this study suggests a potential for Ester-E to benefit cardiovascular health.
Larry Robinson, Ph.D., vice president of scientific affairs for Zila Nutraceuticals, cited two recent findings on vitamin E – the HOPE TOO and Johns Hopkins studies – as both mentioning vitamin E’s pro-oxidant potential as a possible reason why large doses of vitamin E were observed to produce the unexpected results.
“We question the validity of these studies and continue to believe that all forms of vitamin E, including Ester-E are safe. Moreover, in its protected form, Ester-E cannot chemically act as a pro-oxidant. Because of this and the many studies that have been conducted with it, we believe it is not only safe but also acts differently in the body than other forms,” said Robinson. “The exciting potential of Ester-E will continue to be tested in our ongoing human clinical trial with a contract research organization, and our upcoming human clinical trial at the University of Michigan Medical School.”
Ester-E is an advanced form of vitamin E containing d-alpha tocopheryl phosphates (or “TP” for
short). Until recently, scientists were unaware of this important source of vitamin E in the body. Thanks to groundbreaking research, we now know that TP is present in many foods we eat every day – especially dairy products. Additional research suggests that the human body may also convert other forms of vitamin E into TP in order to protect the vitamin’s antioxidant strength until the body is ready to use it. Scientists are now able to replicate this natural form of vitamin E that the body can easily recognize – it is for this reason Ester-E is considered “body ready.”
By joining a phosphate molecule to natural vitamin E in a patented process, Ester-E is able to preserve vitamin E’s natural health benefits until the body is ready to use it. Therefore, Ester-E is protected until it is needed, rather than being used up prematurely.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Visit www.Ester-E.com for more information about Ester-E and other premium products.
*As Ester-E was launched in Summer 2004, comparable year ago comparisons are not available.
About Zila, Inc.
Zila, Inc., headquartered in Phoenix, is an innovator in preventative healthcare technologies and products, focusing on enhanced body defense and the detection of pre-disease states. Zila has three business units:
• Zila Biotechnology, a research, development and licensing business specializing in pre-cancer/cancer detection through its patented Zila® Tolonium Chloride and OraTest® technologies.
• Zila Pharmaceuticals, marketer of products to promote oral health and prevent oral disease, including ViziLite® oral examination kits, Peridex® prescription periodontal rinse and Zilactin® OTC oral care products.
• Zila Nutraceuticals, manufacturer and marketer of Ester-C® and Ester-E®, branded, highly effective forms of Advanced Protection vitamins C and E.
For more information about Zila, visit www.zila.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31, 2004, and its Form 10-Q for the quarter ended January 31, 2005, filed with the Securities and Exchange Commission.
# # #